

BRAINSTORM CELL THERAPEUTICS INC

Form 8-K

June 02, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2011

Brainstorm Cell Therapeutics Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	333-61610 (Commission File No.)	20-8133057 (IRS Employer Identification No.)
---	------------------------------------	---

605 Third Avenue, 34th Floor New York, NY (Address of principal executive offices)	10158 (Zip Code)
--	---------------------

(212) 557-7200  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On June 2, 2011, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing that it intends to adjourn its Annual Meeting of Stockholders to Friday, June 10, 2011, at 9:00 a.m., New York City time at the offices of the Company at 605 Third Avenue, 34th Floor, New York, New York 10158. A copy of the press release issued by the Company concerning the foregoing is included herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The exhibit listed in the Exhibit Index below is filed with this report.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 2, 2011

Brainstorm Cell Therapeutics Inc.

By: /s/ Liat Sossover  
Liat Sossover  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit	Description
No.	Press Release dated June 2, 2011
99.1	

---